Zambia Medicines Regulatory Authority: Kausikh Therapeutics Furosemide Tablets Recall

• The Zambia Medicines Regulatory Authority has issued a recall notice for furosemide tablets 40mg BP manufactured by Kausikh Therapeutics Ltd India.
• Approximately 1,000 packs of the affected product have been distributed in Zambia.
• Healthcare facilities and pharmacies have been instructed to stop dispensing the affected product and return any remaining stock.
• The recall is a regulatory requirement under the Medicines and Allied Substances Act of 2013.
• Lawyers and compliance officers should monitor this recall to ensure their clients' products are not affected.

The authority has instructed all healthcare facilities and pharmacies to immediately stop dispensing the affected product and return any remaining stock to the manufacturer or supplier.

The Zambia Medicines Regulatory Authority (ZMRA) has issued a recall notice for furosemide tablets 40mg BP manufactured by Kausikh Therapeutics Ltd India. The recall affects all batches of the product distributed in Zambia, with a total quantity of approximately 1,000 packs. According to the ZMRA, the decision to recall the product was made due to concerns over its quality and safety. The authority has instructed all healthcare facilities and pharmacies to immediately stop dispensing the affected product and return any remaining stock to the manufacturer or supplier.

The recall notice is a regulatory requirement under the Medicines and Allied Substances Act of 2013, which empowers the ZMRA to take measures to ensure the safety and quality of medicines in Zambia. The authority has a duty to protect public health by monitoring the quality and efficacy of pharmaceutical products distributed within the country. In this case, the recall is a proactive measure aimed at preventing potential harm to patients who may have been prescribed the affected product.

The recall of furosemide tablets 40mg BP manufactured by Kausikh Therapeutics Ltd India has significant implications for healthcare providers, regulatory authorities, and pharmaceutical companies. Lawyers and compliance officers should take note of this recall to ensure that their clients' products are not affected and to be aware of potential supply chain disruptions. The incident highlights the importance of robust quality control measures in the pharmaceutical industry and underscores the need for effective collaboration between regulatory bodies, manufacturers, and healthcare providers to prevent similar incidents in the future.

Lawyers and compliance officers should watch for this recall to ensure their clients' products are not affected, and to be aware of potential supply chain disruptions.

Source: Original reporting via regulatory notice